Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00546286
First received: October 16, 2007
Last updated: April 7, 2015
Last verified: April 2015